Biopharma, Limited Distribution Drugs, Patient Assistance Programs, Rare/Orphan Disease, Specialty HUBs, Specialty Pharmacy

Orsini and PicnicHealth Partner to Improve Rare Disease Patient Care and Real-World Study Execution

Posted on by John Santilli

 

Orsini, a leader in rare disease pharmacy solutions, announced a new partnership with PicnicHealth, a health technology company dedicated to simplifying observational research.

This first-of-its-kind collaboration between health technology and pharmacy solutions collaboration enables rapid development of drug-specific registries that combine real-world drug data, curated EMR, and patient-reported perspectives.

The result is more comprehensive real-world data on approved therapies, providing deeper insights into patient treatment journeys and medication adherence to improve care for rare disease patients.

In 2024, PicnicHealth launched its life sciences research product to simplify observational research and enable life sciences companies to meet study endpoints. Built on world-class artificial intelligence (AI), PicnicHealth goes directly to consented patients to access their universal patient records and capture relevant study data.

This approach enables the rapid creation of drug-specific registries that integrate real-world drug data, curated electronic medical records, and patient-reported outcomes, driving more efficient research and better patient outcomes.

Similarly, Orsini recently launched ORBIT (Orsini Rare Business Intelligence Technology), an AI-powered reporting and analytics platform designed to enhance care for rare disease patients.

By combining their expertise, PicnicHealth and Orsini will generate meaningful insights on patient adherence and long-term outcomes, driving the success of specialized therapies within rare disease populations.

To launch this venture, Orsini and PicnicHealth will partner with AstraZeneca, a global, science-led biopharmaceutical company, to gather insights on WAINUA™ (eplontersen). Orsini is the exclusive specialty pharmacy partner for WAINUA, an FDA-approved treatment for adults living with hereditary transthyretin-mediated amyloid polyneuropathy (commonly referred to as hATTR-PN or ATTRv-PN).

Providing patients with comprehensive and compassionate care since 1987, Orsini is a leader in rare diseases and gene therapies. Recent limited distribution agreements include:

  • Orsini has been selected by Ascendis Pharma as a specialty pharmacy partner for YORVIPATH (palopegteriparatide).
  • Orsini is now distributing BridgeBio’s ATTRUBY (acoramidis), an orally administered treatment for cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM).
  • Orsini has been chosen by Vertex Pharmaceuticals Incorporated to dispense gene-editing therapy CASGEVY (exagamglogene autotemcel).